Harvard Bioscience Inc. (HBIO) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
Harvard Bioscience Inc. (NASDAQ:HBIO) posted its earnings results on Thursday. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.10. Harvard Bioscience had a negative net margin of 18.04% and a positive return on equity of 3.40%.
Harvard Bioscience (NASDAQ:HBIO) traded down 2.13% during trading on Thursday, reaching $2.30. Harvard Bioscience has a 12-month low of $2.25 and a 12-month high of $3.90. The company’s 50-day moving average price is $2.64 and its 200 day moving average price is $2.93. The stock’s market capitalization is $78.92 million.
Large investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC increased its stake in Harvard Bioscience by 27.4% in the second quarter. First Light Asset Management LLC now owns 2,740,203 shares of the company’s stock worth $7,837,000 after buying an additional 590,010 shares during the period. Heartland Advisors Inc. increased its stake in Harvard Bioscience by 7.1% in the second quarter. Heartland Advisors Inc. now owns 2,200,000 shares of the company’s stock worth $6,292,000 after buying an additional 145,778 shares during the period. Dimensional Fund Advisors LP increased its stake in Harvard Bioscience by 0.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,609,704 shares of the company’s stock worth $4,604,000 after buying an additional 14,198 shares during the period. Royce & Associates LP increased its stake in Harvard Bioscience by 17.0% in the first quarter. Royce & Associates LP now owns 1,546,000 shares of the company’s stock worth $4,669,000 after buying an additional 225,000 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Harvard Bioscience by 4.4% in the third quarter. Acadian Asset Management LLC now owns 761,735 shares of the company’s stock worth $2,072,000 after buying an additional 31,956 shares during the period. 66.31% of the stock is owned by institutional investors.
Separately, Zacks Investment Research upgraded shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th.
About Harvard Bioscience
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.